Prime Medicine: on the Path to Curing Rare Diseases with Gene Editor 2.0

Prime Medicine: on the path to curing rare diseases with Gene Editor 2.0   Biotech pioneer focuses on "Prime Editing” – a more precise advancement of CRISPR designed to correct faulty DNA specifically.  Initial clinical data impress investors, but high costs and regulatory hurdles turn the stock into a classic high-risk-high-reward story.  Prime Medicine was founded in 2019 and builds on the work of David Liu at the Broad Institute. The company pursues a visionary approach: Prime Editing. Unlike CRISPR/Cas9, which cuts DNA strands,...